openPR Logo
Press release

Idiopathic Pulmonary Fibrosis Treatment Market Projected to Reach USD 7.81 Billion by 2034, Growing at a 6.9% CAGR

11-08-2024 12:58 PM CET | Health & Medicine

Press release from: Polaris Market Research & Consulting

Idiopathic Pulmonary Fibrosis Treatment Market

Idiopathic Pulmonary Fibrosis Treatment Market

๐ˆ๐๐ข๐จ๐ฉ๐š๐ญ๐ก๐ข๐œ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐š๐ซ๐ฒ ๐…๐ข๐›๐ซ๐จ๐ฌ๐ข๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ-๐Œ๐š๐ซ๐ค๐ž๐ญ Insights, Size Revenue, Outlook, Overview, and Analysis. The idiopathic pulmonary fibrosis treatment market was estimated to be worth USD 4.01 billion in 2024 and is predicted to expand to USD 7.81 billion by 2034, with a CAGR of 6.9% from 2025 to 2034.

๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐’๐œ๐จ๐ฉ๐ž:
This comprehensive study provides an accurate overview of the worldwide idiopathic pulmonary fibrosis treatment market. Comprehensive analyses of sales volume, price, revenue, market share, and important companies are included. The market is further divided into segments by drug class, route of administration, distribution channel, and region in the study, which offers a comprehensive picture of the state of the market.

๐†๐ž๐ญ ๐„๐ฑ๐œ๐ฅ๐ฎ๐ฌ๐ข๐ฏ๐ž ๐’๐š๐ฆ๐ฉ๐ฅ๐ž ๐๐š๐ ๐ž๐ฌ ๐จ๐Ÿ ๐“๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ:
https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/request-for-sample

๐Œ๐š๐ซ๐ค๐ž๐ญ ๐ƒ๐ž๐Ÿ๐ข๐ง๐ข๐ญ๐ข๐จ๐ง:
Idiopathic pulmonary fibrosis (IPF) is a type of interstitial pneumonia characterized by progressive and irreversible lung fibrosis. The condition is defined by the development of scar tissue in the lungs, beginning at the edges and moving towards the center, resulting in breathing complications and inadequate oxygen supply to the body's tissues. Diagnosis involves chest imaging, lung biopsies, pulmonary function tests, and antibody tests. Two popular antifibrotic treatments are medications based on nintedanib and pirfenidone, which enhance lung function and reduce the chances of acute respiratory decline. They are commonly used with oxygen therapy and palliative care to offer comfort and enhance the patient's recovery.

๐ƒ๐ซ๐ข๐ฏ๐ž๐ซ๐ฌ ๐š๐ง๐ ๐“๐ซ๐ž๐ง๐๐ฌ:
โ€ข Older people are at higher risk of developing pulmonary fibrosis because they lose protective stem cells and pericytes as they age, which can cause fibroblast activation and growth. As the world's population gets older, the number of cases of idiopathic pulmonary fibrosis rises.
โ€ข Improvements in diagnostic techniques are greatly contributing to the expansion of the idiopathic pulmonary fibrosis (IPF) treatment market. Enhanced imaging methods like high-resolution computed tomography (HRCT) allow for the earlier and more precise identification of IPF, making timely treatment easier.

๐“๐จ๐ฉ ๐‚๐จ๐ฆ๐ฉ๐š๐ง๐ข๐ž๐ฌ:
The market is marked by fierce competition, and the leading companies rely on innovative technology, superior goods, and a strong brand identity to boost sales.
Here are the top companies in the idiopathic pulmonary fibrosis treatment market:
โ€ข F. Hoffmann-La Roche Ltd
โ€ข Boehringer Ingelheim International GmbH
โ€ข Bristol-Myers Squibb Company
โ€ข Medicinova, Inc
โ€ข Merck & Co., Inc.
โ€ข Galapagos NV
โ€ข Novartis AG
โ€ข Fibrogen, Inc.
โ€ข Avalyn Pharma Inc.
โ€ข Promedior, Inc.

๐‘๐ž๐ช๐ฎ๐ž๐ฌ๐ญ ๐Ÿ๐จ๐ซ ๐š ๐ƒ๐ข๐ฌ๐œ๐จ๐ฎ๐ง๐ญ ๐จ๐ง ๐ญ๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐๐ž๐Ÿ๐จ๐ซ๐ž ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž:
https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/request-for-discount-pricing

๐‚๐จ๐ฎ๐ง๐ญ๐ซ๐ฒ-๐–๐ข๐ฌ๐ž ๐ˆ๐ง๐ฌ๐ข๐ ๐ก๐ญ๐ฌ:
According to regional analysis, North America held the largest revenue share in 2024 because of its advanced healthcare system, effective healthcare regulations and emphasis on research and development are also driving growth in the market in North America.
Also, during the projection period, Asia Pacific is projected to register a significant CAGR because of the increasing occurrence of idiopathic pulmonary fibrosis; increasing knowledge and improved diagnostic techniques are anticipated to drive market expansion in Asia Pacific throughout the forecast period.

๐’๐ž๐ ๐ฆ๐ž๐ง๐ญ๐š๐ฅ ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค:
๐๐ฒ ๐ƒ๐ซ๐ฎ๐  ๐‚๐ฅ๐š๐ฌ๐ฌ ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐”๐’๐ƒ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง, ๐Ÿ๐ŸŽ๐Ÿ๐ŸŽ-๐Ÿ๐ŸŽ๐Ÿ‘๐Ÿ’)
โ€ข Pirfenidone
โ€ข Nintedanib
โ€ข Interferon Gammato1b
โ€ข Others

๐๐ฒ ๐‘๐จ๐ฎ๐ญ๐ž ๐จ๐Ÿ ๐€๐๐ฆ๐ข๐ง๐ข๐ฌ๐ญ๐ซ๐š๐ญ๐ข๐จ๐ง ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐”๐’๐ƒ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง, ๐Ÿ๐ŸŽ๐Ÿ๐ŸŽ-๐Ÿ๐ŸŽ๐Ÿ‘๐Ÿ’)
โ€ข Oral
โ€ข Injectable
โ€ข Others

๐๐ฒ ๐ƒ๐ข๐ฌ๐ญ๐ซ๐ข๐›๐ฎ๐ญ๐ข๐จ๐ง ๐‚๐ก๐š๐ง๐ง๐ž๐ฅ ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐”๐’๐ƒ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง, ๐Ÿ๐ŸŽ๐Ÿ๐ŸŽ-๐Ÿ๐ŸŽ๐Ÿ‘๐Ÿ’)
โ€ข Hospital Pharmacies
โ€ข Retail Pharmacies
โ€ข Others

๐๐ฒ ๐‘๐ž๐ ๐ข๐จ๐ง๐š๐ฅ ๐Ž๐ฎ๐ญ๐ฅ๐จ๐จ๐ค (๐”๐’๐ƒ ๐๐ข๐ฅ๐ฅ๐ข๐จ๐ง, ๐Ÿ๐ŸŽ๐Ÿ๐ŸŽ-๐Ÿ๐ŸŽ๐Ÿ‘๐Ÿ’)
โ€ข North America
โ€ข Europe
โ€ข Asia Pacific
โ€ข Latin America
โ€ข Middle East & Africa

๐ˆ๐ง๐ช๐ฎ๐ข๐ซ๐ž ๐ฆ๐จ๐ซ๐ž ๐š๐›๐จ๐ฎ๐ญ ๐ญ๐ก๐ข๐ฌ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐๐ž๐Ÿ๐จ๐ซ๐ž ๐๐ฎ๐ซ๐œ๐ก๐š๐ฌ๐ž:
https://www.polarismarketresearch.com/industry-analysis/idiopathic-pulmonary-fibrosis-treatment-market/inquire-before-buying

๐ˆ๐๐ข๐จ๐ฉ๐š๐ญ๐ก๐ข๐œ ๐๐ฎ๐ฅ๐ฆ๐จ๐ง๐š๐ซ๐ฒ ๐…๐ข๐›๐ซ๐จ๐ฌ๐ข๐ฌ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐Œ๐š๐ซ๐ค๐ž๐ญ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ ๐‡๐ข๐ ๐ก๐ฅ๐ข๐ ๐ก๐ญ๐ฌ
โ€ข Based on route of administration, the oral segment is anticipated to register a significant CAGR in the global market during the forecast period. This growth is attributed to its several advantages, including ease of use and potential of outpatient management.
โ€ข By distribution channel, the hospital pharmacies segment accounted for the largest revenue share of the market in 2024 due to increasing hospitalization rates and the availability of specialized care for patients requiring advanced treatments.
โ€ข In 2024, North America accounted for the largest revenue share of the global idiopathic pulmonary fibrosis treatment market due to its advanced medical infrastructure
โ€ข The idiopathic pulmonary fibrosis treatment market in India is projected for significant growth during the forecast period due to the increased investments in its pharmaceutical manufacturing sector.
โ€ข A few global key market players are F. Hoffmann-La Roche Ltd; Boehringer Ingelheim International GmbH; Bristol-Myers Squibb Company; Medicinova, Inc; Merck & Co., Inc.; Galapagos NV; Novartis AG; and Fibrogen, Inc.

๐‘๐ž๐ฅ๐š๐ญ๐ž๐ ๐‘๐ž๐ฉ๐จ๐ซ๐ญ:
๐“๐ž๐ฅ๐ž๐ซ๐š๐๐ข๐จ๐ฅ๐จ๐ ๐ฒ ๐’๐จ๐Ÿ๐ญ๐ฐ๐š๐ซ๐ž ๐Œ๐š๐ซ๐ค๐ž๐ญ
https://www.polarismarketresearch.com/industry-analysis/teleradiology-software-market

๐๐ž๐ž๐๐ฅ๐ž ๐‡๐จ๐ฅ๐๐ž๐ซ ๐Œ๐š๐ซ๐ค๐ž๐ญ
https://www.polarismarketresearch.com/industry-analysis/needle-holder-market

๐’๐ญ๐ž๐ซ๐ข๐ฅ๐ž ๐ˆ๐ง๐ฃ๐ž๐œ๐ญ๐š๐›๐ฅ๐ž ๐‚๐จ๐ง๐ญ๐ซ๐š๐œ๐ญ ๐Œ๐š๐ง๐ฎ๐Ÿ๐š๐œ๐ญ๐ฎ๐ซ๐ข๐ง๐  ๐Œ๐š๐ซ๐ค๐ž๐ญ
https://www.polarismarketresearch.com/industry-analysis/sterile-injectable-contract-manufacturing-market

๐‚๐ž๐ฅ๐ฅ ๐๐ซ๐จ๐œ๐ž๐ฌ๐ฌ๐ข๐ง๐  ๐ˆ๐ง๐ฌ๐ญ๐ซ๐ฎ๐ฆ๐ž๐ง๐ญ๐ฌ ๐Œ๐š๐ซ๐ค๐ž๐ญ
https://www.polarismarketresearch.com/industry-analysis/cell-processing-instruments-market

๐ƒ๐ข๐ ๐ข๐ญ๐š๐ฅ ๐—-๐‘๐š๐ฒ ๐Œ๐š๐ซ๐ค๐ž๐ญ
https://www.polarismarketresearch.com/industry-analysis/digital-x-ray-market

Contact:
Likhil G
8 The Green Ste 19824,
Dover, DE 19901,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Follow Us: LinkedIn | Twitter

About Polaris Market Research & Consulting, Inc:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR's clientele spread across different enterprises. We at Polaris are obliged to serve PMR's diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR's customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR's customers.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic Pulmonary Fibrosis Treatment Market Projected to Reach USD 7.81 Billion by 2034, Growing at a 6.9% CAGR here

News-ID: 3725593 • Views: โ€ฆ

More Releases from Polaris Market Research & Consulting

Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of 5.2%
Granite Market Projected to Reach USD 6.63 Billion by 2034, Growing at a CAGR of โ€ฆ
Polaris Market Research has released new insights into the Granite market, highlighting key developments, evolving trends, and growth prospects across major regions and segments. The report delivers an in-depth analysis of market dynamics, competitive shifts, and strategic outlooks to support informed decision-making for businesses and investors. Market at a Glance In 2024, the market was valued at USD 3.99 billion and is anticipated to grow to USD 6.63 Billion by 2034. Itโ€ฆ
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 Billion by 2034, Growing at a CAGR of 7.5%
Molecular Diagnostics for Sexually Transmitted Diseases Market to Reach USD 7.85 โ€ฆ
Polaris Market Research announces the release of its latest study on the Molecular Diagnostics For Sexually Transmitted Diseases market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape. According to the findings, the market stood at 3.82 billion in 2024 and is expected toโ€ฆ
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expanding at a CAGR of 6.8%
Higher Alpha Olefins Market Projected to Hit USD 20.01 Billion by 2034, Expandin โ€ฆ
Polaris Market Research announces the release of its latest study on the Higher Alpha Olefins market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape. According to the findings, the market stood at 10.39 billion in 2024 and is expected to reach 20.01 billionโ€ฆ
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2034, Growing at a CAGR of 7.44%
Direct Oral Anticoagulants (DOACs) Device Market to Reach USD 64.83 Billion by 2 โ€ฆ
Polaris Market Research announces the release of its latest study on the Direct Oral Anticoagulants (DOACs) Device market. It offers comprehensive insights into all the key market aspects, including industry trends, market dynamics, competitive landscape, and strategic developments. The report is designed to help stakeholders make strategic decisions in the rapidly evolving market landscape. According to the findings, the market stood at 31.67 billion in 2024 and is expected to reachโ€ฆ

All 5 Releases


More Releases for Idiopathic

Idiopathic Pulmonary Fibrosis Market Size & Share Analysis
The new report published by The Business Research Company, titled Idiopathic Pulmonary Fibrosis Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends. As per the report, the idiopathic pulmonary fibrosis market size has grown strongly in recent years. It will grow from $3.89โ€ฆ
Idiopathic Pulmonary Fibrosis Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Idiopathic Pulmonary Fibrosis Pipeline Insight 2024" report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. โ€ฆ
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry. The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,โ€ฆ
Idiopathic Membranous Nephropathy Treatment Market to Witness Significant Growth โ€ฆ
Idiopathic membranous nephropathy a glomerular disease usually of abrupt onset and associated with the nephrotic syndrome. Membranous nephropathy occurs when the small blood vessels in the kidney (glomeruli), which filter wastes from the blood, become damaged and thickened. As a result, proteins leak from the damaged blood vessels into the urine (proteinuria). R&D in idiopathic membranous nephropathy is expected to aid in growth of the idiopathic membranous nephropathy treatment market. Inโ€ฆ
Global Idiopathic Scoliosis Treatment Market Size by Type (Infantile Idiopathic, โ€ฆ
Global Idiopathic Scoliosis Treatmentโ€Žโ€Žโ€Žโ€Žโ€Žโ€Žโ€Ž Market Research report provides vital information related to the overall market and forecast from 2019 to 2026. This report includes the in-depth analysis of market size, share, growth, trends and regional demand and top layers the Idiopathic Scoliosis Treatmentโ€Žโ€Žโ€Žโ€Žโ€Žโ€Žโ€Ž Market. The major players dominating the market are focused upon throughout the by analyzing their revenue, their business summary, product segmentation along with the latest developments. Get Sampleโ€ฆ
Chronic Idiopathic Constipation Market Research Report 2024
Constipation can be defined as reduced stool frequency or difficulty in passing stool. The frequency may be reduced to less than three times a week. Reduced or difficult stool passage includes hard lumpy stools, incomplete bowel movements, straining, incomplete evacuation, and need for manual removal of stool. Chronic idiopathic constipation (CIC) can be defined as more chronic or severe continuation of these above symptoms. Many times the cause of constipationโ€ฆ